PL2026775T3 - Zastosowanie inhibitorów kinazy tyrozynowej Syk w leczeniu komórkowych zaburzeń proliferacyjnych - Google Patents

Zastosowanie inhibitorów kinazy tyrozynowej Syk w leczeniu komórkowych zaburzeń proliferacyjnych

Info

Publication number
PL2026775T3
PL2026775T3 PL07804842T PL07804842T PL2026775T3 PL 2026775 T3 PL2026775 T3 PL 2026775T3 PL 07804842 T PL07804842 T PL 07804842T PL 07804842 T PL07804842 T PL 07804842T PL 2026775 T3 PL2026775 T3 PL 2026775T3
Authority
PL
Poland
Prior art keywords
treatment
tyrosine kinase
kinase inhibitors
cell proliferative
proliferative disorders
Prior art date
Application number
PL07804842T
Other languages
English (en)
Inventor
Eliahu Kaplan
Original Assignee
Novaremed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaremed Ltd filed Critical Novaremed Ltd
Publication of PL2026775T3 publication Critical patent/PL2026775T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL07804842T 2006-05-09 2007-05-09 Zastosowanie inhibitorów kinazy tyrozynowej Syk w leczeniu komórkowych zaburzeń proliferacyjnych PL2026775T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79910306P 2006-05-09 2006-05-09
PCT/IB2007/002471 WO2007129226A2 (en) 2006-05-09 2007-05-09 Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
EP07804842.8A EP2026775B1 (en) 2006-05-09 2007-05-09 Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders

Publications (1)

Publication Number Publication Date
PL2026775T3 true PL2026775T3 (pl) 2015-12-31

Family

ID=38668152

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07804842T PL2026775T3 (pl) 2006-05-09 2007-05-09 Zastosowanie inhibitorów kinazy tyrozynowej Syk w leczeniu komórkowych zaburzeń proliferacyjnych

Country Status (12)

Country Link
US (3) US20090306214A1 (pl)
EP (1) EP2026775B1 (pl)
JP (1) JP5225264B2 (pl)
AU (1) AU2007246779B2 (pl)
CA (1) CA2651375C (pl)
DK (1) DK2026775T3 (pl)
ES (1) ES2542344T3 (pl)
HU (1) HUE026820T2 (pl)
IL (1) IL195152A (pl)
PL (1) PL2026775T3 (pl)
PT (1) PT2026775E (pl)
WO (1) WO2007129226A2 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7642290B2 (en) * 2002-10-03 2010-01-05 Novaremed Limited Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
US7674829B2 (en) * 2004-03-26 2010-03-09 Novaremed Limited Compounds for the treatment of AIDS and other viral diseases
GB0804213D0 (en) * 2008-03-06 2008-04-16 New Era Biotech Ltd A method of printing or preventing pain
US8802734B2 (en) * 2009-09-09 2014-08-12 Novaremed Limited Method of treating or preventing pain
WO2011030205A1 (en) * 2009-09-09 2011-03-17 Novaremed Ltd. N-substituted benzenepropanamide or benzenepropenamide for use in the treatment of pain and inflammation
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
KR20160013204A (ko) 2013-05-30 2016-02-03 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4185279A4 (en) 2020-07-24 2024-05-01 Secura Bio, Inc. TREATING CANCER WITH PI3-KINASE ISOFORM MODULATORS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1908322A (en) * 1932-04-07 1933-05-09 Claude R Cook Weed puller
US2908691A (en) * 1958-07-14 1959-10-13 Searle & Co Hydroxyphenalkylaminoalkylindoles and ethers corresponding thereto
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
US7642290B2 (en) * 2002-10-03 2010-01-05 Novaremed Limited Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
US7674829B2 (en) * 2004-03-26 2010-03-09 Novaremed Limited Compounds for the treatment of AIDS and other viral diseases

Also Published As

Publication number Publication date
AU2007246779B2 (en) 2013-11-28
CA2651375A1 (en) 2007-11-15
WO2007129226A2 (en) 2007-11-15
US20120108666A1 (en) 2012-05-03
US20140039060A1 (en) 2014-02-06
WO2007129226A3 (en) 2008-05-08
EP2026775B1 (en) 2015-04-29
ES2542344T3 (es) 2015-08-04
HUE026820T2 (en) 2016-07-28
DK2026775T3 (en) 2015-06-29
US20090306214A1 (en) 2009-12-10
JP5225264B2 (ja) 2013-07-03
AU2007246779A1 (en) 2007-11-15
EP2026775A2 (en) 2009-02-25
IL195152A0 (en) 2009-09-22
JP2009536191A (ja) 2009-10-08
IL195152A (en) 2015-10-29
PT2026775E (pt) 2015-08-05
CA2651375C (en) 2015-12-22

Similar Documents

Publication Publication Date Title
IL195152A0 (en) Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
EP2063897A4 (en) KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES
EP2063896A4 (en) KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES
IL266741A (en) Broton tyrosine kinase inhibitors
IL201650A0 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
IL196998A0 (en) Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
IL197933A0 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
IL202505A0 (en) 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumors
AU2009270856A8 (en) Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
ZA201000106B (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
ZA201000087B (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
PT2120932E (pt) Derivados de indazol como inibidores da quinase para tratamento do cancro
IL190935A0 (en) 4-(3-aminopyrazole)pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
PL2203449T3 (pl) Heterocykliczne związki bicykliczne jako inhibitory białkowej kinazy tyrozynowej
PL2197880T3 (pl) Heterocykliczne związki bicykliczne jako inhibitory białkowej kinazy tyrozynowej
ZA201004055B (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
IL188390A0 (en) Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
AP2886A (en) 6.7-Dialkoxy quinazoline derivatives useful for treatment of cancer related disorders
IL184997A0 (en) Use of tyrosine kinase inhibitors for the treatment of chronic rhinosinusitis
IL187895A0 (en) Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
ZA200901015B (en) Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
ZA200704735B (en) Use of tyrosine kinase inhibitors for the treatment of chronic rhinosinusitis
ZA201009085B (en) Dihydropyrazole derivatives as tyrosine kinase modulators for the treatment of tumors
ZA200710136B (en) Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
ZA200803582B (en) 4-(3-Aminopyrazole) Pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer